Literature DB >> 24756358

(68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma.

Emre Demirci1, Meltem Ocak, Levent Kabasakal, Clemens Decristoforo, Zübeyir Talat, Metin Halaç, Bedii Kanmaz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24756358     DOI： 10.1007/s00259-014-2766-y

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  4 in total

1.  Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen.

Authors:  S S Chang; V E Reuter; W D Heston; P B Gaudin
Journal:  Urology       Date:  2001-04       Impact factor: 2.649

2.  A comparative study of metastatic renal cell carcinoma with correlation to subtype and primary tumor.

Authors:  K T Mai; D C Landry; S J Robertson; A S Commons; B F Burns; A Thijssen; J Collins
Journal:  Pathol Res Pract       Date:  2001       Impact factor: 3.250

3.  Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms.

Authors:  Angelo Baccala; Linda Sercia; Jianbo Li; Warren Heston; Ming Zhou
Journal:  Urology       Date:  2007-08       Impact factor: 2.649

4.  PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.

Authors:  A Afshar-Oromieh; A Malcher; M Eder; M Eisenhut; H G Linhart; B A Hadaschik; T Holland-Letz; F L Giesel; C Kratochwil; S Haufe; U Haberkorn; C M Zechmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-24       Impact factor: 9.236
  4 in total
  49 in total

1.  (68)Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma.

Authors:  Arun Sasikumar; Ajith Joy; Raviteja Nanabala; M R A Pillai; Boben Thomas; K R Vikraman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-08       Impact factor: 9.236

2.  68Ga-Prostate-Specific Membrane Antigen, A Potential Radiopharmaceutical in PET/CT To detect primary Cholangiocarcinoma.

Authors:  Rita Chahinian; Ahmad El-Amine; Sayed Matar; Mostafa Annan; Ali Shamseddine; Mohamad Haidar
Journal:  Asia Ocean J Nucl Med Biol       Date:  2020

3.  Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [18F]DCFPyL PET/CT.

Authors:  Yafu Yin; Scott P Campbell; Mark C Markowski; Philip M Pierorazio; Martin G Pomper; Mohamad E Allaf; Steven P Rowe; Michael A Gorin
Journal:  Mol Imaging Biol       Date:  2019-06       Impact factor: 3.488

4.  First evidence of PSMA expression in differentiated thyroid cancer using [⁶⁸Ga]PSMA-HBED-CC PET/CT.

Authors:  Frederik A Verburg; Thomas Krohn; Alexander Heinzel; Felix M Mottaghy; Florian F Behrendt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-04-28       Impact factor: 9.236

5.  ⁶⁸Ga-PSMA imaging of metastatic breast cancer.

Authors:  Mike Sathekge; Moshe Modiselle; Mariza Vorster; Neo Mokgoro; Nozipho Nyakale; Brenda Mokaleng; Thomas Ebenhan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-05-01       Impact factor: 9.236

6.  The reconstruction algorithm used for [68Ga]PSMA-HBED-CC PET/CT reconstruction significantly influences the number of detected lymph node metastases and coeliac ganglia.

Authors:  Thomas Krohn; Anita Birmes; Oliver H Winz; Natascha I Drude; Felix M Mottaghy; Florian F Behrendt; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-11-29       Impact factor: 9.236

7.  68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.

Authors:  Wolfgang P Fendler; Matthias Eiber; Mohsen Beheshti; Jamshed Bomanji; Francesco Ceci; Steven Cho; Frederik Giesel; Uwe Haberkorn; Thomas A Hope; Klaus Kopka; Bernd J Krause; Felix M Mottaghy; Heiko Schöder; John Sunderland; Simon Wan; Hans-Jürgen Wester; Stefano Fanti; Ken Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06       Impact factor: 9.236

8.  Molecular imaging using PSMA PET/CT versus multiparametric MRI for initial staging of prostate cancer: comparing apples with oranges?

Authors:  Felix M Mottaghy; Alexander Heinzel; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-27       Impact factor: 9.236

Review 9.  Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer.

Authors:  Steven P Rowe; Alexander Drzezga; Bernd Neumaier; Markus Dietlein; Michael A Gorin; Michael R Zalutsky; Martin G Pomper
Journal:  J Nucl Med       Date:  2016-10       Impact factor: 10.057

10.  Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT.

Authors:  Steven P Rowe; Michael A Gorin; Hans J Hammers; M Som Javadi; Hazem Hawasli; Zsolt Szabo; Steve Y Cho; Martin G Pomper; Mohamad E Allaf
Journal:  Ann Nucl Med       Date:  2015-08-19       Impact factor: 2.668
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.